It has also been shown that the use of TNF-α blockers in complex therapy causes a decrease in the frequency of initiation of cardiovascular events in patients with rheumatoid arthritis (RA), the high density lipoproteins (HDL) cholesterol content increases and the level of CRP and IL-6 decreases after 2 weeks of use. This evidence concerns the gene TNF and rheumatoid arthritis.